Core Viewpoint - Shanghai Pharmaceuticals has received drug registration certificates from the Philippines Food and Drug Administration for its Oxytocin Injection and Acetate Octreotide Injection, allowing these products to be marketed [2] Group 1 - Shanghai Pharmaceuticals announced the approval of its Oxytocin Injection and Acetate Octreotide Injection for sale in the Philippines [2] - The approval signifies a potential expansion of the company's market presence in Southeast Asia [2]

Core Viewpoint - Shanghai Pharmaceuticals has received drug registration certificates from the Philippines Food and Drug Administration for its oxytocin injection and octreotide acetate injection, allowing for market entry in the Philippines [1] Group 1: Product Approval - The oxytocin injection is primarily used for induction and labor [1] - The octreotide acetate injection is mainly used for treating acromegaly [1] Group 2: Financial Implications - The company did not incur additional R&D expenses for the product registration, with only registration costs amounting to approximately RMB 50,000 [1] - The approval signifies the company's eligibility to sell these products in the Philippine market, which is expected to positively impact its overseas market expansion [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceutical First Biochemical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the oxytocin injection and octreotide acetate injection, allowing these drugs to be marketed [1] Group 1: Product Approvals - The oxytocin injection is primarily used for induction of labor, postpartum hemorrhage, and assessing placental reserve function [1] - The octreotide acetate injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyuan Biochemical Pharmaceutical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the approval of Oxytocin Injection and Acetate Octreotide Injection for market launch [1] Group 1: Product Approvals - Oxytocin Injection is primarily used for induction of labor, postpartum hemorrhage due to uterine atony, and assessing placental reserve function [1] - Acetate Octreotide Injection is mainly used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical, has received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines, allowing them to enter the market without significant R&D costs [1] Group 1: Product Details - Oxytocin is used for induction of labor and was approved in China in 1994 [1] - Octreotide acetate is used for treating acromegaly and was approved in China in 2006, passing the consistency evaluation for generic drugs in 2022 [1] Group 2: Market Impact - The sales forecast for oxytocin in the Philippines is estimated at $970,000 in 2024 [1] - The approval of these drugs is expected to help expand the company's overseas market presence [1] Group 3: Financial Considerations - The registration costs for these drugs were approximately 50,000 yuan, with no additional R&D expenses incurred [1] - Sales may face uncertainties due to factors such as policy changes and exchange rate fluctuations [1]

Core Viewpoint - Shanghai Pharmaceuticals Holding Co., Ltd. is a major pharmaceutical group listed in both Shanghai and Hong Kong, focusing on innovation and health improvement [1] Group 1: Stock Performance - On August 18, the Shanghai Composite Index rose by 0.85%, closing at 3728.03 points, while the Hang Seng Index fell by 0.37%, closing at 25176.85 points [1] - Shanghai Pharmaceuticals' A-shares closed at 18.95 yuan, with an increase of 0.74%, while its H-shares closed at 12.67 Hong Kong dollars, decreasing by 0.39% [1] Group 2: Company Overview - Shanghai Pharmaceuticals is included in the Shanghai Stock Exchange 180 Index, the CSI 300 Index, and the Morgan Stanley China Index (MSCI) [1] - The company promotes core values of "innovation, integrity, cooperation, inclusiveness, and responsibility," aiming to enhance public health and become a respected leading brand in pharmaceutical manufacturing and health services [1] Group 3: Business Strategy - The company is committed to continuous innovation and has been increasing its investment in research and development to accelerate its transformation [1]

董事會會議通告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 董事會會議將於二零二五年八月二十八日（星期四）舉行，藉以（其中包括） 批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績及其 發佈。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年八月十八日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 * 僅供識別 ...

Core Viewpoint - Recently, Shanghai Pharmaceuticals (601607) established a new subsidiary, Up Pharmaceutical Holdings (Yongzhou) Co., Ltd., with a registered capital of 20 million yuan, indicating an expansion in its operational capabilities in the pharmaceutical sector [1] Company Summary - The new company is co-owned by Shanghai Pharmaceuticals' subsidiary, Up Pharmaceutical Holdings (Hunan) Co., Ltd., and Yongzhou Big Health Industry Co., Ltd., reflecting a strategic partnership in the health industry [1] - The business scope of the new entity includes drug wholesale, sales of Class II and III radiation devices, operation of Class III medical devices, general equipment repair, and professional design services, showcasing a diverse range of services [1]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 726,500 yuan [1] Group 1: Salary Distribution - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] - The average annual salary for company secretaries in the pharmaceutical commercial sector is 726,500 yuan [1] - Salary distribution shows that 43% earn below 500,000 yuan, 36% earn between 500,000 and 1 million yuan, 18% earn between 1 million and 2 million yuan, and 3% earn above 2 million yuan [1] Group 2: Age and Education Distribution - Company secretaries aged between 40-50 years constitute 57% of the market, while those over 50 years account for 11%, and those aged 40 or below make up 32% [1] - The educational background of company secretaries shows that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one individual holding a PhD [1] Group 3: Notable Salary Changes - The highest-paid company secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [1] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [1]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1-2 million yuan, and 3% above 2 million yuan [2] - The top three highest-paid secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]